qxp 1 4 09 23:39 Page 05 Hikma Pharmaceuticals PLC 05 Annual report 2008 Operational highlights of 2008 Group performance Group revenues up 29% to $580.7 million with 63% of revenues generated in MENA $ million 2008 2007 2006 Operating cash ow 75.0 53.3 35.3 Capital expenditure 56.7 49.4 53.2 Adjusted profit attributable to shareholders Net debt -170.9 -306.8 25.0 1 up 4.5% to $67.4 million Net debt equity 28% 72% ns Dividend per share cents 7.5 7.5 7.0 Branded revenues up 61% to $321 million reecting 2007 gures restated.
2 strong organic growth of 22% Injectables revenues up 23% to $149 million, reecting 3 organic growth of 14%.
Injectables revenues in MENA grew by 43%, and in the US by 29% Generics business returned to profit in Q4 2008 following management changes and operational improvements Operating cash ow up 41% to $75 million through strong focus on working capital management Net debt reduced by 44% to $171 million 1 profit before amortisation of intangible assets other than software and exceptional items.
2 Excluding the impact of Hikma Egypt and APM acquired in 2007.
3 Excluding the impact of APM and Thymoorgan in 2007.
